Learn about plans for clinical evaluation of ARAKODA® (tafenoquine) for COVID-19 disease.


Positive Phase II Study Data Suggest ARAKODA® (tafenoquine) Numerically Improved Clinical Recovery in Patients with Mild-Moderate COVID-19 Disease

Developing therapeutic innovations that can significantly improve and extend people’s lives.

In 2010, 60° Pharmaceuticals began its mission to build a better world by undertaking research and action focused on aiding in the prevention of tropical diseases.

Escalating malaria care around the world

Escalating malaria care
to people in need around
the world

Advancing therapies for the treatment and prevention of malaria.

Meeting the global dengue endemic

Meeting the challenges of
the global dengue endemic

With only one vaccine commercially available in the US to effectively combat dengue fever, 60P is poised to enter the dengue fever treatment arena.

For the Investment Community

For the investment community

We are committed to serving the best interests of our investors.

Our team is committed to creating innovative, potentially lifesaving medicines to significantly impact the quality of life for those affected by tropical diseases worldwide.


Annual deaths from malaria globally


Travelers to endemic regions per annum


Dengue infections per year


1025 Connecticut Ave. NW, Suite 1000, Washington, DC 20036